Promise for patients with metastatic renal cell carcinoma

Affiliations

Comment

Eric A Klein. Nat Clin Pract Urol. 2007 Feb.

. 2007 Feb;4(2):72-3.

doi: 10.1038/ncpuro0704.

¹ The Cleveland Clinic Foundation, Desk A100, 9500 Euclid Avenue, Cleveland, OH 44195, USA. kleine@ccf.org

No abstract available

Comment on

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ. Ratain MJ, et al. J Clin Oncol. 2006 Jun 1;24(16):2505-12. doi: 10.1200/JCO.2005.03.6723. Epub 2006 Apr 24. J Clin Oncol. 2006. PMID: 16636341 Clinical Trial.